Archives of Pharmaceutical Sciences and Research E-ISSN 0975-2633 | PRINT ISSN 0975-5284
Vol 16 Issue 1 017 – 021 March 2026 Review Article

DESIGN AND DEVELOPMENT OF 3D TARGETED HYDROGEL FOR PREBIOTIC-PROBIOTIC-MICRONUTRIENTS DELIVERY TO IMPROVE GUT AND HORMONAL HEALTH IN WOMEN

Lavanya S, Beny Baby, Honnushree.A, Abhinaya.J, Tanuja Chabbi, Sadha.M.S

Department of Pharmaceutics, Karnataka College of Pharmacy, Bangalore -560064.

ABSTRACT

Women's hormonal health is closely interlinked with gut physiology, microbiota composition, nutritional status, and life-stage-specific endocrine changes. Hormonal disorders such as premenstrual syndrome (PMS), polycystic ovary syndrome (PCOS), perimenopause, postmenopause-associated metabolic disturbances, and postpartum depression are highly prevalent among women of reproductive and post-reproductive age. Emerging evidence highlights the gut-hormone axis, wherein gut microbiota modulates estrogen metabolism, insulin sensitivity, cortisol regulation, and neurotransmitter synthesis.[1][2]

Conventional pharmacotherapy often provides symptomatic relief but is associated with long-term adverse effects and limited patient adherence.Nutritional and microbiome-based interventions, particularly probiotics, prebiotics, and micronutrients, offer a promising, safer, and holistic alternative. However, their oral delivery is challenged by gastric degradation, poor intestinal retention, and variable bioavailability.

Three-dimensional (3D) gut-targeted hydrogel systems represent an innovative drug-delivery platform capable of protecting bioactives, enabling controlled release, and improving site-specific action in the gastrointestinal tract.

This review critically discusses hormonal imbalance in women across life stages, the role of nutrition and microbiome-targeted therapies, and the mechanistic basis of probiotics, prebiotics, and micronutrients in restoring gut and hormonal health. Special emphasis is placed on the design and development of 3D gut-targeted hydrogels for combined delivery of probiotics, prebiotics, and micronutrients, their role in maintaining gut homeostasis, clinical applications, limitations, research gaps, and future directions.[2][3]

KEYWORDS

3D hydrogel; gut-targeted delivery; probiotics; prebiotics; micronutrients; women's hormonal health; PCOS; PMS; menopause; postpartum depression; gut-hormonal axis.

INTRODUCTION

Hormonal Balance in Women Across Reproductive Life Stages

Hormonal balance in women is a dynamic physiological process regulated by the hypothalamic-pituitary-gonadal (HPG) axis and influenced by metabolic, immune, and gastrointestinal systems. During reproductive age, cyclical variations in estrogen, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) are essential for menstrual regularity, fertility, and overall well-being. Across life stages-adolescence, reproductive years, perimenopause, menopause, and postmenopause-hormonal fluctuations become more pronounced, often predisposing women to endocrine and metabolic disorders. Prevalence of Hormonal Disorders.[2][4]

Hormonal disorders are highly prevalent among women worldwide. PMS affects approximately 50-80% of menstruating women, while PCOS impacts 6-20% of women of reproductive age. Perimenopause and menopause are associated with vasomotor symptoms, mood disturbances, osteoporosis, and cardiovascular risks.

Postpartum depression affects nearly 10-15% of women after childbirth. Emerging evidence suggests that these conditions share common underlying factors, including gut dysbiosis, inflammation, insulin resistance, and micronutrient deficiencies.

Role of Nutrition and Therapies in Hormonal Imbalance.[4][5]

Nutritional status plays a pivotal role in maintaining endocrine health. Deficiencies in iron, zinc, magnesium, B-complex vitamins, vitamin D, and omega-3 fatty acids are frequently observed in women with hormonal disorders.[4] Pharmacological therapies such as hormonal contraceptives, insulin sensitizers, and antidepressants provide symptomatic relief but may cause adverse effects and fail to address gut-related dysfunctions. Nutritional and microbiota-targeted interventions offer a holistic and safer alternative.

Influence of Prebiotics, Probiotics, and Micronutrients on Gut and Hormonal Health

Prebiotics and Probiotics modulate gut microbiota composition, enhance intestinal barrier integrity, and regulate immune and endocrine signaling. The gut microbiota, particularly the estrobolome, plays a crucial role in estrogen metabolism and enterohepatic circulation. Micronutrients act as cofactors in hormone synthesis, neurotransmitter regulation, and antioxidant defense.[7]

Mechanisms and Disease Impact 1. Premenstrual Syndrome (PMS)

Causes & Pathophysiology: PMS involves cyclical mood disturbance, somatic symptoms (bloating, cramps), and metabolic changes linked to progesterone and serotonin dysregulation. Inflammation and altered gut–brain signalling are implicated. Mechanism of Gut-Hormone Interaction: Symbiosis may reduce SCFA production, impacting tryptophan metabolism and serotonin synthesis. Elevated gut permeability leads to systemic inflammation affecting hypo thalamic–pituitary–gonadal (HPG) axis. [17][18]. Therapeutic Role: Prebiotics: Enhance beneficial Bifidobacterium that increases SCFAs, improving serotonin pathways. Probiotics: *Lactobacillus acidophilus* may reduce inflammatory cytokines, improving mood and cramps. Micronutrients: Vitamin B6 supports neurotransmitter synthesis (serotonin, GABA); magnesium relaxes smooth muscle reducing cramps. Target Hormones: Serotonin, progesterone, estrogen.[17][18]

2.Polycystic Ovary Syndrome (PCOS)

Causes & Pathophysiology: PCOS is characterized by hyperandrogenism, insulin resistance, and chronic low-grade inflammation. Dysbiosis is often observed with reduced microbial diversity. Mechanism of Gut–Hormone Interaction: Dysbiosis increases lipopolysaccharide (LPS), promoting insulin resistance. SCFAs affect GLP-1 and PYY, influencing appetite and insulin sensitivity.[15] Therapeutic Role: Prebiotics: Inulin and FOS improve insulin sensitivity via SCFA stimulation. Probiotics: Bifidobacterium longum, Lactobacillus rhamnosus and Lactobacillus helvetics reduce systemic inflammation and improve metabolic profiles. Micronutrients: Vitamin D modulates immune response; inositol improves insulin signaling. Target Hormones: Insulin, androgens (testosterone), GLP-1.[15][16]

3. Perimenopause & Menopausal Transition

Causes & Pathophysiology: Declining ovarian function alters estrogen/progesterone levels, affecting thermoregulation, bone density, mood, and metabolic health. Mechanism of Gut–Hormone Interaction: Reduced estrogen alters microbiota composition (“menobolic microbiome”) and increases inflammation.[10] Altered SCFA levels affect bone metabolism and central neurotransmission. Therapeutic Role: Prebiotics: Increase beneficial microbes to stabilize estrobolome activity. Probiotics: Reduce vasomotor symptoms and modulate inflammation. Micronutrients: Calcium and vitamin D preserve bone health; B vitamins support mood. Target Hormones: Estrogen, FSH, serotonin.[10]

4.Post Menopause

Causes & Pathophysiology: Persistent hypoestrogenism leads to osteoporosis, metabolic syndrome, and urogenital atrophy. Mechanism of Gut–Hormone Interaction: Estrogen deficiency exacerbates gut barrier dysfunction and systemic inflammation. Microbial SCFAs influence lipid metabolism.[10] Therapeutic Role: Prebiotics & Probiotics: Improve lipid profiles and reduce inflammation. Micronutrients: Vitamin D and calcium for bone health; omega-3 fatty acids for cardiovascular support. Target Hormones: Estrogen, leptin, adiponectin.[10]

5.Postpartum Depression (PPD)

Causes & Pathophysiology: Rapid hormonal shifts (estrogen, progesterone) postpartum, along with immune activation and stress response, predispose to PPD. Mechanism of Gut–Hormone Interaction: Gut dysbiosis influences the HPA (hypothalamic–pituitary–adrenal) axis, affecting cortisol levels. Microbial signals influence tryptophan metabolism and neuroinflammation.[13] Therapeutic Role: Prebiotics: Promote resilience in gut–brain axis by modulating SCFA and vagal pathways. Probiotics: Lactobacillus helveticus shown to reduce anxiety/depressiogenic markers. Micronutrients: Omega-3 fatty acids, zinc, vitamin D support neurogenesis and reduce inflammation. Target Hormones: Cortisol, serotonin, estrogen.[5][13][14]

Design and Development of 3D Gut-Targeted Hydrogels 1. Rationale for Hydrogel Delivery

Hydrogels are crosslinked polymeric networks capable of encapsulating live probiotics, prebiotic fibers, and micronutrients. Advantages include: Protection from gastric acidity and bile salts. Controlled release at targeted intestinal sites. Improved viability of live bacteria.[6][7][8]

2. Key Design Parameters

Polymer Selection: Biocompatible polymers like alginate, chitosan, carrageenan tailored for pH responsiveness. Encapsulation Efficiency: Optimizing pore size and crosslink density for survival of live microbes and stability of micronutrients. Targeted Release: Use of enteric coatings and pH-responsive degradation to release payload in small and large intestines. Mechanical Stability: Ensuring resilience during peristalsis and gastric transit.[6][7]

3.Mechanistic Delivery Profile

Upon oral administration:

Gastric Protection: Acid-resistant outer layer preserves bioactives. pH-Triggered Swelling: In ileum/colon, hydrogel swells, releasing prebiotics and micronutrients. Microbial Colonization: Encapsulated probiotics reimplant to existing microbiota. Metabolic Activation: Prebiotics feed native and delivered probiotics facilitating SCFA production and metabolic modulation.[6][7]

Maintenance of Gut Health by Prebiotic-Probiotic-Micronutrient Hydrogels

Microbial Diversity Enhancement: Increased populations of beneficial strains and competitive exclusion of pathogens. Improved Barrier Function: SCFA production enhances tight junction proteins (claudin, occludin). Immune Modulation: Reduction of pro-inflammatory cytokines (IL-6, TNF-α) and augmentation of Treg cells.[7][9] Metabolic Signaling: SCFA-mediated GLP-1 and PYY release supports glucose homeostasis.

Clinical Applications and Recommendations 1 .Potential Clinical Indications

PMS symptom mitigation. Metabolic improvement in PCOS Peri/postmenopausal symptom management Prevention of osteoporosis. Reduction in PPD incidence[9]

2 .Therapeutic Protocols

Personalized Combinations: Tailored probiotic strains (e.g., L. rhamnosus, B. lactis), prebiotic fibers, and individualized micronutrient dosing.

Adjunct to Conventional Therapies: Integration with hormonal or metabolic treatments.

Monitoring: Microbiome profiling and hormonal assays to assess treatment response.[9]

Limitations and Therapeutic Incompatibilities 1.Biological Challenges

Stability of Probiotics: Variable survival rates despite encapsulation. Compatibility of Micronutrients: Certain micronutrients may inhibit probiotic growth. Immunogenic Potential: Exogenous strains may elicit immune reactions in susceptible individuals.[11]

2.Delivery Constraints

Release Kinetics Issues: Premature degradation or delayed release. Gastrointestinal Variability: Interindividual differences in pH and transit time affect delivery.[12]

Research Gaps and Future Directions

Strain-Specific Effects: More RCTs to delineate strain and dose responses. Hydrogel Optimization: Advanced materials (bio-inks, stimuli-responsive polymers) to improve targeting. Systems Biology Integration: Multi-omics analyses to map gut-endocrine networks. Long-Term Outcomes: Large cohort studies on prolonged use and safety. Regulatory Frameworks: Guidelines for live biotherapeutic product (LBP) classification and quality standards.[11][12]

CONCLUSION

The intersection of gut microbiota modulation and hormone regulation presents a compelling avenue for improving women's health across reproductive stages. 3D gut-targeted hydrogels co-delivering probiotics, prebiotics, and micronutrients offer a sophisticated, controlled, and synergistic therapeutic modality. Current evidence supports mechanistic plausibility and emerging clinical benefits, particularly in PMS, PCOS, menopausal transitions, and mood disorders. Nonetheless, optimization of delivery systems, rigorous clinical validation, and personalized therapeutic frameworks are required to translate this innovation into standard care.

REFERENCES

1. Baker, J. M., Al-Nakkash, L., & Herbst-Kralovetz, M. M. (2017). Estrogen–gut microbiome axis: Physiological and clinical implications. Maturitas, 103, 45–53.
2. Santoro, N., & Randolph, J. F. (2011). Reproductive hormones and the menopause transition. Obstetrics & Gynecology Clinics of North America, 38, 455–466.
3. Burger, H. G. (2002). The endocrinology of the menopause. Journal of Steroid Biochemistry and Molecular Biology, 83, 31–35.
4. Yonkers, K. A., et al. (2008). Premenstrual syndrome. The Lancet, 371, 1200–1210.
5. Slykerman, R. F., et al. (2017). Effect of Lactobacillus rhamnosus HN001 on postpartum depression and anxiety. EBioMedicine, 24, 159–165.
6. Gholizadeh Shamasbi, S., et al. (2019). Probiotic supplementation improves metabolic status in PCOS. Journal of Functional Foods, 58, 293–299.
7. Markowiak, P., & Śliżewska, K. (2017). Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients, 9, 1021.
8. Reid, G., et al. (2013). Microbiota restoration: Natural and supplemented probiotics. Clinical Pharmacology & Therapeutics, 93, 192–196.
9. Caló, E., & Khutoryanskiy, V. V. (2015). Biomedical applications of hydrogels. European Polymer Journal, 65, 252–267.
10. Gao, X., et al. (2018). The gut microbiota and menopause. Menopause, 25, 859–866.
11. Peppas, N. A., et al. (2006). Hydrogels in pharmaceutical formulations. European Journal of Pharmaceutics and Biopharmaceutics, 64, 2–7.
12. Siepmann, J., & Siepmann, F. (2012). Modeling of diffusion controlled drug delivery. International Journal of Pharmaceutics, 418, 42–53.
13. Stewart, D. E., & Vigod, S. N. (2016). Postpartum depression. New England Journal of Medicine, 375, 2177–2186.

14. 14.Bloch, M., et al. (2003). Effects of gonadal steroids in women with a history of postpartum depression. American Journal of Psychiatry, 160, 163–165.
15. Torres, P. J., et al. (2018). Gut microbiome diversity in women with PCOS. Human Reproduction, 33, 1859–1868.
16. Zhang, J., et al. (2019). Dysbiosis of gut microbiota in PCOS. Journal of Clinical Endocrinology & Metabolism, 104, 1659–1669. 7.Wyatt, K. M., et al. (1999). Efficacy of vitamin B6 in treating PMS. BMJ, 318, 1375–1381. 18.Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol. 1991;78(2):177–181.